Objective: To assess the protective effect of goserelin on the ovarian function of premenopausal patients with breast cancer during chemotherapy.
Methods: The clinical data of premenopausal patients with breast cancer treated in the recent two-year period were retrospectively analyzed. The patients were divided into study group (goserelin plus conventional chemotherapy) and control group (conventional chemotherapy) with 40 cases in each group. The menstrual status and the hormone levels during chemotherapy and first year follow-up after chemotherapy between the two groups were observed. 
Results: All the 80 patients completed their chemotherapy treatment and all of them developed menstrual disorders. The menstrual recovery rate of the observation group and the control group was 85% and 55%， respectively， and the difference between the two groups had statistical significance (P=0.007). In the observation group， the serum oestradiol (E2) decreased to postmenopausal level， and the serum levels of follicle stimulating hormone (FSH) were also significantly decreased during combination treatment (goserelin plus conventional chemotherapy). In the control group， the E2 levels decreased gradually while FSH and LH level increased significantly during chemotherapy.
Conclusions: Goserelin administration during chemotherapy can effectively prevent the ovarian function injury caused by chemotherapy， and can help maintain normal menstruation and fertility for the young and middle-aged patients.